ClinicalTrials.gg
CompletedNCT03180684Updated Aug 25, 2023Results posted

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

A Phase 2 interventional study of VGX-3100 and Imiquimod 5% Cream in Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia and Vulvar Intraepithelial Neoplasia (VIN), sponsored by Inovio Pharmaceuticals. Completed at 15 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by Inovio Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Squamous Intraepithelial Lesions with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Squamous Intraepithelial Lesions · United States.

Enrollment
24th of 39
33 · median 48
Started
2017
with 4 others
Phase 2
19 of 44
4 open now
Registered
24th of 44
by date
Lead sponsor
4 of 44
Inovio Pharmaceuticals

Among the 44 studies in Squamous Intraepithelial Lesions with a site in United States, this one is the 24th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2017, is one of 19 in phase 2, and was the 24th registered.

Squamous Intraepithelial Lesions

104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.

Browse Squamous Intraepithelial Lesions studies →

Open to participants now

7 of the 44 studies in Squamous Intraepithelial Lesions with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Squamous Intraepithelial Lesions with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) [vulval intraepithelial neoplasia 2 or 3 (VIN 2 or VIN 3)] associated with human papilloma virus (HPV) types 16 and/or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com

03

Conditions studied

  • Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
  • Vulvar Dysplasia
  • Vulvar Intraepithelial Neoplasia (VIN)
  • VIN2
  • VIN3
  • Pre-cancerous Lesions of the Vulva
  • Human Papillomavirus (HPV)

Keywords

  • HPV-16
  • HPV-18
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 and above;
  • Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;

Exclusion criteria

Exclusion Criteria:

  • -proven differentiated VIN;
  • Any previous treatment for vulvar HSIL within 4 weeks prior to screening;
  • Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;
  • Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of product;
  • as a result of underlying illness or treatment;
  • Significant acute or chronic medical illness.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    VGX-3100 + EP

    Participants with histologically confirmed vulvar high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) 16 and/or 18, received four doses of 6 mg VGX-3100 as an intramuscular (IM) injection on Day 0, Week 4, Week 12, and Week 24 followed by electroporation (EP) using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.

    Biological: VGX-3100 · Device: CELLECTRA™ 2000

  • Experimental
    VGX-3100 + EP + Imiquimod

    Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.

    Biological: VGX-3100 · Drug: Imiquimod 5% Cream · Device: CELLECTRA™ 2000

Interventions

  • BiologicalVGX-3100

    One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.

  • Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.

  • DeviceCELLECTRA™ 2000

    IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples

    A treatment responder for the primary endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or vulvar low grade squamous intraepithelial lesions (LSIL) \[vulval intraepithelial neoplasia 1 (VIN1)\] or condyloma) and no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product. A TEAE was defined per protocol as any AE with onset after the administration of study medication through the end of the study (i.e., study discharge).

    Time frame: 7 days following each dose: Day 0 (Days 0 to 7), Week 4 (Days 22 to 28), Week 12 (Days 78 to 84), Week 24 (Days 162 to 168), and Week 52 (Days 358 to 364)

  2. Percentage of Participants With Adverse Events (AEs)

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product.

    Time frame: From baseline up to Week 100

  3. Percentage of Participants With No Histologic Evidence of Vulvar HSIL

    Participants with no histologic evidence of vulvar HSIL (normal tissue or vulvar LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) were considered. All lesions were evaluated for histologic evidence of vulvar HSIL.

    Time frame: Week 48

  4. Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples

    Participants with no evidence of HPV-16 and/or HPV-18 indicated the clearance of the specific HPV genotypes \[16, 18, or both\]. All lesions were evaluated for evidence of HPV-16/18 in vulvar tissue.

    Time frame: Week 48

  5. Percentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue

    A treatment responder for the endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) or no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.

    Time frame: Week 48

  6. Percentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology

    Histologic regression was defined as a participant with no histologic evidence of vulvar HSIL, no evidence of LSIL (VIN1), and no evidence of condyloma. Histologic regression of vulvar HSIL to normal tissue was assessed.

    Time frame: Week 48

  7. Percentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer

    Non-progression of vulvar HSIL to vulvar cancer was evaluated from baseline to Week 48. Progression was defined as advancement to carcinoma by histology.

    Time frame: From baseline up to Week 48

  8. Percent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)

    Lesion(s), defined as areas that stain acetowhite were assessed. Analysis of qualifying lesions was defined as the change in total surface area of only lesions with both baseline and Week 48 measurements. Percent change in the cumulative surface area of the acetowhite vulvar lesion(s) was determined by the quantitative analysis of standardized prebiopsy photographic imaging of qualifying lesion(s) at Week 48 compared to baseline.

    Time frame: From baseline to Week 48

  9. Change From Baseline in Interferon-Gamma (IFN-γ) Response Magnitude

    Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples. Assessment of cellular immune activity was performed by IFN-γ enzyme-linked immunosorbent spot-forming (ELISpot) assay.

    Time frame: Baseline; Weeks 15, 27, 48, 74, and 96

  10. Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations

    A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.

    Time frame: Weeks 15, 27, 48, 74, and 96

  11. Change From Baseline in Flow Cytometry Response Magnitude

    Assessment of cellular immune activity was measured using the application of flow cytometry for the purpose of performing a Lytic Granule Loading Assay. The Lytic Granule Loading Assay examines the following external cellular markers: cluster of differentiation 3 (CD3), CD4, CD8 (T-cell identification), CD137, CD38, and CD69 (T-cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, a change from baseline in CD8+/CD137+ PBMCs expressing Perforin+ was reported.

    Time frame: Baseline; Week 27

07

Results

Posted Aug 25, 2023

Participant flow

Participants were enrolled at 20 study sites in the United States from 31 August 2017 to 18 December 2020.

Participant flow — Overall Study
MilestoneVGX-3100 + EPVGX-3100 + EP + Imiquimod
Started258
Modified intent-to-treat (mitt) population258
Safety population258
Completed178
Not completed80
Withdrew: Withdrawal by subject (not related to ae)50
Withdrew: Physician decision10
Withdrew: Lost to follow-up10
Withdrew: Progressive disease10

Outcome measures

PrimaryPercentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples

A treatment responder for the primary endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or vulvar low grade squamous intraepithelial lesions (LSIL) \[vulval intraepithelial neoplasia 1 (VIN1)\] or condyloma) and no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples15.0 (3.2 to 37.9)37.5 (8.5 to 75.5)
Statistical analysis
  • VGX-3100 + EP · Clopper Pearson · p = 0.0071A 1-sided p-value was calculated to prove superiority over historical control of 2%. Superiority of VGX-3100 alone was declared if p-value is \<0.025.
  • VGX-3100 + EP + Imiquimod · Clopper Pearson · p = 0.00041-sided p-value was calculated to prove superiority over historical control of 2%.Superiority of VGX-3100+imiquimod was declared if p-value is \<0.025.
SecondaryPercentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product. A TEAE was defined per protocol as any AE with onset after the administration of study medication through the end of the study (i.e., study discharge).

Time frame:
7 days following each dose: Day 0 (Days 0 to 7), Week 4 (Days 22 to 28), Week 12 (Days 78 to 84), Week 24 (Days 162 to 168), and Week 52 (Days 358 to 364)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With at Least One Local and Systemic Treatment-emergent Adverse Event (TEAE) During 7 Days Following Each Dose84.0 (63.92 to 95.46)75.0 (34.91 to 96.81)
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product.

Time frame:
From baseline up to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With Adverse Events (AEs)92.0100
SecondaryPercentage of Participants With No Histologic Evidence of Vulvar HSIL

Participants with no histologic evidence of vulvar HSIL (normal tissue or vulvar LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) were considered. All lesions were evaluated for histologic evidence of vulvar HSIL.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Histologic Evidence of Vulvar HSIL
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Histologic Evidence of Vulvar HSIL15.0 (3.2 to 37.9)37.5 (8.5 to 75.5)
SecondaryPercentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples

Participants with no evidence of HPV-16 and/or HPV-18 indicated the clearance of the specific HPV genotypes \[16, 18, or both\]. All lesions were evaluated for evidence of HPV-16/18 in vulvar tissue.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples15.0 (3.2 to 37.9)50.0 (15.7 to 84.3)
SecondaryPercentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue

A treatment responder for the endpoint was defined as a participant with no histologic evidence of vulvar HSIL (normal tissue or LSIL \[VIN1\] or condyloma) based on histology (i.e. biopsies or excisional treatment) or no evidence of HPV-16 or HPV-18 (i.e., elimination of the specific genotypes \[16, 18, or both\]) in vulvar tissue at evaluation and who did not receive any non-study related treatment for vulvar HSIL. All lesions were evaluated for histologic evidence of vulvar HSIL or evidence of HPV-16/18 in vulvar tissue.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Histologic Evidence of Vulvar HSIL or No Evidence of HPV-16/18 in Vulvar Tissue15.0 (3.2 to 37.9)50.0 (15.7 to 84.3)
SecondaryPercentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology

Histologic regression was defined as a participant with no histologic evidence of vulvar HSIL, no evidence of LSIL (VIN1), and no evidence of condyloma. Histologic regression of vulvar HSIL to normal tissue was assessed.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Evidence of Vulvar HSIL, No Evidence of Vulvar LSIL (VIN1), and No Evidence of Condyloma on Histology10.0 (1.2 to 31.7)37.5 (8.5 to 75.5)
SecondaryPercentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer

Non-progression of vulvar HSIL to vulvar cancer was evaluated from baseline to Week 48. Progression was defined as advancement to carcinoma by histology.

Time frame:
From baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer
percentage of participantsVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percentage of Participants With No Progression of Vulvar HSIL to Vulvar Cancer100.0 (83.2 to 100.0)100.0 (63.1 to 100.0)
SecondaryPercent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)

Lesion(s), defined as areas that stain acetowhite were assessed. Analysis of qualifying lesions was defined as the change in total surface area of only lesions with both baseline and Week 48 measurements. Percent change in the cumulative surface area of the acetowhite vulvar lesion(s) was determined by the quantitative analysis of standardized prebiopsy photographic imaging of qualifying lesion(s) at Week 48 compared to baseline.

Time frame:
From baseline to Week 48
Reported as:
Mean · percent change in surface area
Percent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)
percent change in surface areaVGX-3100 + EPVGX-3100 + EP + Imiquimod
Percent Change From Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)47.7 ± 249.6210.5 ± 117.95
SecondaryChange From Baseline in Interferon-Gamma (IFN-γ) Response Magnitude

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples. Assessment of cellular immune activity was performed by IFN-γ enzyme-linked immunosorbent spot-forming (ELISpot) assay.

Time frame:
Baseline; Weeks 15, 27, 48, 74, and 96
Reported as:
Median · spot forming units (SFU) per 10^6 cells
Change From Baseline in Interferon-Gamma (IFN-γ) Response Magnitude
spot forming units (SFU) per 10^6 cellsVGX-3100 + EPVGX-3100 + EP + Imiquimod
HPV-16 E6 (Baseline)1.667 (0.00 to 35.00)1.667 (0.00 to 8.33)
HPV-16 E6 (Change From Baseline at Week 15)0.833 (0.00 to 78.33)0.000 (0.00 to 43.33)
HPV-16 E6 (Change From Baseline at Week 27)0.833 (0.00 to 58.33)3.333 (0.00 to 36.67)
HPV-16 E6 (Change From Baseline at Week 48)0.833 (0.00 to 56.67)0.000 (0.00 to 3.33)
HPV-16 E6 (Change From Baseline at Week 74)1.667 (0.00 to 30.00)0.000 (0.00 to 25.00)
HPV-16 E6 (Change From Baseline at Week 96)1.667 (0.00 to 38.33)0.833 (0.00 to 8.33)
HPV-16 E7 (Baseline)1.667 (0.00 to 15.00)0.000 (0.00 to 1.67)
HPV-16 E7 (Change From Baseline at Week 15)3.333 (0.00 to 43.33)1.667 (0.00 to 56.67)
HPV-16 E7 (Change From Baseline at Week 27)3.333 (0.00 to 71.67)6.667 (0.00 to 40.00)
HPV-16 E7 (Change From Baseline at Week 48)1.667 (0.00 to 31.67)1.667 (0.00 to 25.00)
HPV-16 E7 (Change From Baseline at Week 74)1.667 (0.000 to 15.00)0.833 (0.00 to 21.67)
HPV-16 E7 (Change From Baseline at Week 96)0.000 (0.000 to 3.33)0.000 (0.00 to 0.00)
HPV-18 E6 (Baseline)0.000 (0.00 to 6.67)0.000 (0.00 to 6.67)
HPV-18 E6 (Change From Baseline at Week 15)19.167 (0.00 to 593.33)10.000 (1.67 to 123.33)
HPV-18 E6 (Change From Baseline at Week 27)10.833 (0.00 to 908.33)5.000 (0.00 to 146.67)
HPV-18 E6 (Change From Baseline at Week 48)14.167 (0.00 to 566.67)3.333 (0.00 to 80.00)
HPV-18 E6 (Change From Baseline at Week 74)8.333 (0.00 to 925.00)9.167 (0.00 to 45.00)
HPV-18 E6 (Change From Baseline at Week 96)20.000 (0.00 to 63.33)19.167 (1.67 to 48.33)
HPV-18 E7 (Baseline)0.000 (0.00 to 11.67)0.000 (0.00 to 3.33)
HPV-18 E7 (Change From Baseline at Week 15)2.500 (0.00 to 51.67)3.333 (0.00 to 16.67)
HPV-18 E7 (Change From Baseline at Week 27)1.667 (0.00 to 33.33)6.667 (0.00 to 43.33)
HPV-18 E7 (Change From Baseline at Week 48)1.667 (0.00 to 51.67)0.000 (0.00 to 21.67)
HPV-18 E7 (Change From Baseline at Week 74)1.667 (0.00 to 20.00)0.000 (0.00 to 6.67)
HPV-18 E7 (Change From Baseline at Week 96)3.333 (0.00 to 5.00)4.167 (0.00 to 13.33)
SecondaryLevels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations

A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.

Time frame:
Weeks 15, 27, 48, 74, and 96
Reported as:
Geometric mean · reciprocal endpoint titer
Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations
reciprocal endpoint titerVGX-3100 + EPVGX-3100 + EP + Imiquimod
Anti-HPV-16 (Week 15)7.3 ± 3.2213.1 ± 2.89
Anti-HPV-16 (Week 27)9.6 ± 3.2415.0 ± 3.07
Anti-HPV-16 (Week 48)15.9 ± 3.3317.2 ± 3.06
Anti-HPV-16 (Week 74)14.5 ± 3.316.1 ± 2.80
Anti-HPV-16 (Week 96)37.0 ± 3.1311.4 ± 2.85
Anti-HPV-18 (Week 15)24.8 ± 3.73133.7 ± 4.32
Anti-HPV-18 (Week 27)44.7 ± 3.6789.4 ± 4.85
Anti-HPV-18 (Week 48)69.3 ± 3.87133.7 ± 4.36
Anti-HPV-18 (Week 74)83.2 ± 3.9845.0 ± 4.23
Anti-HPV-18 (Week 96)2.9 ± 1.862.2 ± 1.61
SecondaryChange From Baseline in Flow Cytometry Response Magnitude

Assessment of cellular immune activity was measured using the application of flow cytometry for the purpose of performing a Lytic Granule Loading Assay. The Lytic Granule Loading Assay examines the following external cellular markers: cluster of differentiation 3 (CD3), CD4, CD8 (T-cell identification), CD137, CD38, and CD69 (T-cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, a change from baseline in CD8+/CD137+ PBMCs expressing Perforin+ was reported.

Time frame:
Baseline; Week 27
Reported as:
Median · SFU/10^6 PBMC
Change From Baseline in Flow Cytometry Response Magnitude
SFU/10^6 PBMCVGX-3100 + EPVGX-3100 + EP + Imiquimod
Baseline0.150 (0.00 to 14.50)1.250 (0.00 to 3.35)
Change from Baseline at Week 270.000 (0.00 to 18.70)0.000 (0.00 to 7.70)

Adverse events

Collected over From the first injection up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VGX-3100 + EP0/25 (0%)3/25 (12%)23/25 (92%)
VGX-3100 + EP + Imiquimod0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventVGX-3100 + EPVGX-3100 + EP + Imiquimod
Back painMusculoskeletal and connective tissue disorders1/250/8
UlcerGeneral disorders1/250/8
CellulitisInfections and infestations1/250/8
Pulmonary massRespiratory, thoracic and mediastinal disorders1/250/8
Most frequent other events
Showing 10 of 64
Most frequent other events
EventVGX-3100 + EPVGX-3100 + EP + Imiquimod
Injection site painGeneral disorders18/256/8
FatigueGeneral disorders14/254/8
MyalgiaMusculoskeletal and connective tissue disorders12/254/8
NauseaGastrointestinal disorders10/253/8
Injection site bruisingGeneral disorders10/250/8
HeadacheNervous system disorders10/253/8
Injection site swellingGeneral disorders9/253/8
Injection site erythemaGeneral disorders8/253/8
ArthralgiaMusculoskeletal and connective tissue disorders6/253/8
PyrexiaGeneral disorders1/252/8

Baseline characteristics

mITT population included all participants who received at least 1 dose of VGX-3100 + EP (with or without imiquimod) and had an analysis endpoint of interest.

Age, Continuous
Age, Continuous(years)VGX-3100 + EPVGX-3100 + EP + ImiquimodTotal
Mean50.2 ± 12.8645.4 ± 9.1349.1 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)VGX-3100 + EPVGX-3100 + EP + ImiquimodTotal
Female25833
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VGX-3100 + EPVGX-3100 + EP + ImiquimodTotal
Hispanic or Latino202
Not Hispanic or Latino23831
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VGX-3100 + EPVGX-3100 + EP + ImiquimodTotal
Race — Black or African303
Race — White21829
Race — Other101
Region of Enrollment
Region of Enrollment(participants)VGX-3100 + EPVGX-3100 + EP + ImiquimodTotal
United States25833
08

Study locations

15 sites
  • Christiana Care Health Systems
    Newark, Delaware 19713, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Maine Medical Center
    Scarborough, Maine 04074, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • St. Dominic Hospital
    Jackson, Mississippi 39216, United States
  • Rutgers New Jersey
    Newark, New Jersey 07103, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Complete HealthCare for Women, Inc.
    Columbus, Ohio 43231, United States
  • University of Pittsburgh Medical Center - Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Chattanooga's Program in Women's Oncology
    Chattanooga, Tennessee 37403, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2519, United States
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jul 2020, 34 months.

Results were first posted in Aug 2023, 3 years 1 month after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2017
First posted
Jun 8, 2017
StartActual
Aug 31, 2017
Primary completionActual
Jul 23, 2020
CompletionActual
Dec 18, 2020
Results delay requested
Jul 16, 2021
Results first posted
Aug 25, 2023
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03180684
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Aug 31, 2017
Primary completion
Jul 23, 2020
Completion
Dec 18, 2020
Results posted
Aug 25, 2023
Last update
Aug 25, 2023

Study contacts

Jeffrey Skolnik, MD
study director · Inovio Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VGX-3100

Start the discussion